Prognostic and clinicopathological significance of SNHG20 in human cancers: a meta-analysis

Hanlong Zhu†, Si Zhao†, Ruonan Jiao, Huishan Wang, Ruiyi Tang, Xiaochao Wu, Fei Wang, Xianxiu Ge, Quanpeng Li and Lin Miao*†

Abstract

Background: It has been widely reported that the expression levels of SNHG20 are elevated in diverse types of cancers, indicating that SNHG20 may participate in cancer initiation and development. Besides, accumulating evidence reveals that SNHG20 overexpression is also connected with poor clinical outcomes among cancer patients. Herein, we carry out a systematic meta-analysis to further determine the prognostic and clinical significance of SNHG20 expression in various human cancers.

Methods: Qualifying publications were selected by searching for keywords in PubMed, Embase, Web of Science and Cochrane Library databases, up to September 1, 2019. Pooled hazard ratio (HR) or odds ratio (OR) with corresponding 95% confidence interval (CI) was computed to estimate the strength of association between SNHG20 and survival of cancer patients or clinicopathology using Stata 14.0 software.

Results: In total, 15 studies encompassing 1187 patients met the inclusion criteria were ultimately enrolled for analysis. According to the meta-analysis, patients with high SNHG20 expression were markedly linked to poorer overall survival (OS) (pooled HR = 2.47, 95% CI 2.05–2.98, P = 0.000) and disease-free survival/recurrence-free survival/progression-free survival (DFS/RFS/PFS) (pooled HR = 2.37, 95% CI 1.60–3.51, P = 0.000). Additionally, regarding clinicopathology of patients, enhanced SNHG20 was correlated with advanced tumour-node-metastasis (TNM) stage (OR = 2.80, 95% CI 2.00–3.93, P = 0.000), larger tumor size (OR = 3.08, 95% CI 2.11–4.51, P = 0.000), positive lymph nodes metastasis (OR = 2.99, 95% CI 2.08–4.31, P = 0.000), higher tumor stage (OR = 4.51, 95% CI 2.17–9.37, P = 0.000) and worse histological grade (OR = 1.95, 95% CI 1.44–2.63, P = 0.000), but not with gender, smoking status or distant metastasis.

Conclusions: Up-regulated SNHG20 expression is ubiquitous in different kinds of cancers. Moreover, up-regulated SNHG20 expression is capable of serving as an innovative predictive factor of inferior clinical outcomes in cancer patients. Nevertheless, higher-quality multicenter studies are required to corroborate our results.

Keywords: SNHG20, lncRNA, Cancer, Prognosis, Meta-analysis

Background

Cancer has become one of the common chronic diseases that seriously threatens human health and imposes an immense burden on society. The upward trend of cancer gives rise to worldwide concern, with almost 1,762,450 newly diagnosed cancer cases and
approximately 606,880 cancer-related deaths in the United States in 2019 [1]. Although the survival benefit of multidisciplinary synthetic therapy is recognized, the prognosis in patients with terminal stages of cancer remains unsatisfactory [2]. To this end, the identification of an accurate biomarker for cancer prognosis is of great clinical value, which can be applied to early diagnosis and targeted therapy for clinical practice.

More recently, with the advent of next-generation sequencing technologies, long noncoding RNAs (lncRNAs), as a new category of noncoding transcripts, have come into the spotlight [3]. By definition, lncRNAs constitute a large and heterogeneous subset of RNAs that are distinguished by a length of greater than 200 nucleotides and the absence of protein-coding capability [4]. They were once regarded as simply genomic “junk” so that they having been underappreciated for a long time [5]. Nonetheless, lncRNAs have emerged as functional molecules, which serve pivotal roles in diverse biological processes, with clear relevance to cancer [5]. Additionally, accumulating shreds of evidence unveil that lncRNAs can exert oncogenic or tumor-suppressing effects in tumorigenesis and progression [6], suggesting that lncRNAs may be candidate markers for cancer diagnosis, prognosis, and therapeutics.

The small nucleolar RNA host gene 20 (SNHG20) has arrested our attention among the lncRNAs, which stems from chromosome 17q25.2 and harbors 2183 basepairs [7]. Initially, SNHG20 was discovered in hepatocellular carcinoma (HCC) and has been proved to function as an oncogene in HCC [8]. Subsequently, a growing body of research has identified that aberrant SNHG20 expression definitely interacted with prognostic outcomes and clinicopathological characteristics in patients with many kinds of malignancies, including bladder cancer [9], osteosarcoma [10], glioma [11], colorectal cancer [12], gastric cancer [13], lung cancer [14], cervical cancer [15], esophageal carcinoma [16], oral carcinoma [17], nasopharyngeal carcinoma [18], ovarian cancer [19], and laryngeal carcinoma [20]. Consistently, overexpression of SNHG20 could promote cell-cycle, proliferation, invasion, and migration of tumor cells via different mechanisms, while up-regulated SNHG20 is an unfavorable prognostic factor [7]. It should be taken into account that most individual studies are restricted by controversial and discrete conclusions as well as small sample size. For the sake of comprehensively validating the underlying prognostic and clinicopathological role of SNHG20 in various malignancy patients, a quantitative meta-analysis is therefore undertaken.

Materials and methods

Literature search strategies

Up to September 1, 2019, potential eligible literature were systematically retrieved in four authoritative databases including PubMed, Embase, Web of Science and Cochrane Library databases to obtain pertinent articles regarding prognostic and clinicopathological features of SNHG20 among various tumors. The searched keywords in variably combinations were as following: (“small nucleolar RNA host gene 20” OR “SNHG20”) AND (“cancer” OR “carcinoma” OR “tumor” OR “neoplasm”) AND (“prognosis” OR “prognostic”). The reference lists of included studies were also checked to identify potential relevant papers.

Inclusion and exclusion criteria

The research involved in this meta-analysis were asked to meet the following preassigned criteria: (1) investigated the roles of SNHG20 in multiple human tumors, (2) detected the expression levels of SNHG20 in cancer tissue, (3) divided the patients into dichotomous groups according to the specific criteria for SNHG20 expression levels, (4) reported data related with the clinicopathological characteristics and prognostic information of the patients, and (5) had sufficient data for calculating the hazard ratios (HR) with corresponding 95% confidence intervals (CI). All these studies were not included because of the any of the following reasons: (1) stated reduplicative research, (2) offered insufficient or unavailable data, (3) were reviews, letters, case reports, editorials, expert opinions, conference reports, and animal experiments, and (4) published in a non-English language.

Literature screening and data extraction

Two investigators (Hanlong Zhu, Si Zhao) independently screened the literature following the prespecified criteria described above and extracted the data. Any conflicts were resolved through consensus with a third scholar (Ruonan Jiao). The following information was collected from each enrolled study: lead author name, publication year, region, carcinoma type, sample size (high/low), SNHG20 assessment method and the cut-off approximations for SNHG20 expression levels, the clinicopathological parameters including age, gender, smoking status, tumour-node-metastasis (TNM) stage, tumor size, lymph node metastasis, tumor stage, histological grade, and distant metastasis, together with HR and 95% CI for overall survival (OS), disease-free survival (DFS), recurrence-free survival (RFS) and progression-free survival (PFS). If only Kaplan–Meier curves existed in some articles, HR and 95% CI were determined with available data using the published method [21, 22].
Quality evaluation
The quality of eligible publications was calculated based on the Newcastle–Ottawa Scale (NOS) that evaluated the selection of cohorts, comparability as well as exposure or outcome and had a score ranging from 0 to 9. Studies with higher or equal to 6 points could be considered as high quality (Table 1).

Statistical analysis
The pooled HR with corresponding 95% CI was utilized to estimate the relationship between SNHG20 expression and patients’ prognosis. While the effect of SNHG20 expression on clinicopathological features was described as the combined odds ratio (OR) and matching 95% CI. Cochran’s Q and I^2 tests were applied for checking the heterogeneity of the results. A P value < 0.1 suggested having statistical significance, whereas I^2 values > 50% indicated the existence of significant heterogeneity. When there was homogeneous data, the fixed-effect framework was adopted, otherwise, the random-effect model was employed. Besides, probable publication bias was quantified with conducting Begg’s test and Egger’s test, respectively. Sensitivity analysis was also done to investigate the stability of the accumulated results. All analyses were carried out using Stata 14.0 software. P value < 0.05 was regarded as being statistically significant.

Results
Data selection and characteristics
According to the search strategy, 89 relevant records were initially retrieved from four electronic databases. Three publications were enrolled by manually searching the reference lists. After ruling out the duplicates, 45 studies were left for further assessment. Next, 17 papers were directly removed by carefully scanning titles and abstracts. For the remaining 28 articles, 13 articles were excluded owing to lack of sufficient data. Ultimately, 15 studies showing agreement with the inclusion criteria were selected for entering in the meta-analysis (Fig. 1).

The attributes of the research studies involved in the present analysis are summarized in Table 1. These studies containing 1187 cancer patients had an accrual period between 2016 and 2019 and sample sizes varying from 32 to 144 (mean, 79). Each and every research study was performed in China; two studies referred to hepatocellular carcinoma [8, 23], two studies involved osteosarcoma [10, 24], two studies touched upon glioma [11, 25], and the remaining nine studies related to colorectal cancer [12], gastric cancer [13], lung cancer [14], cervical cancer [15], esophageal carcinoma [16], oral carcinoma [17], nasopharyngeal carcinoma [18], ovarian cancer [19], and laryngeal carcinoma [20]. The whole subjects registered were separated into high and low SNHG20 group on the basis of the SNHG20 measurement results. Moreover, 14 studies used quantitative reverse transcription polymerase chain reaction (qRT-PCR) for the detection of SNHG20 expression in tumor tissues while only one study chose in situ hybridization (ISH). Most articles preferred to exploit the median value as the Cut-off value for high or low SNHG20 expression. Regarding survival outcomes, all of the cohorts reported patients’ OS, of which four cohorts simultaneously presented DFS/RFS/PFS. Among the studies, HR and 95% CI were provided in five original articles and indirectly reckoned from survival curves in the rest of ten papers. Overall, all these qualified studies were recognized to be of high quality in this meta-analysis.

Association between SNHG20 expression and survival of cancer patients

SNHG20 expression and OS
A total of fifteen studies comprising 1187 patients focused on assessing the effect of SNHG20 overexpression on OS in various kinds of cancer. As illustrated in Fig. 2a, a fixed-effect framework was applied because of the lack of significant heterogeneity among these studies (I^2 = 0.0%, P = 0.718). The pooled HR suggested that the high SNHG20 expression group showed a statistically obvious decline in OS (pooled HR = 2.47, 95% CI 2.05–2.98, P = 0.000). In addition, subgroup analyses were performed regarding cancer types, sample sizes and data extraction methods to further analyze the predictive value of SNHG20 (Fig. 2b–d, Table 2). In the stratified analysis by type of cancers, promoted SNHG20 expression status was closely related to worse OS of the patients with respiratory system cancers (pooled HR = 3.78, 95% CI 1.18–12.09, P = 0.025, fixed-effect), gliomas (pooled HR = 3.27, 95% CI 1.84–5.82, P = 0.000, fixed-effect), digestive system cancers (pooled HR = 2.91, 95% CI 2.16–3.92, P = 0.000, fixed-effect), head and neck cancers (pooled HR = 1.97, 95% CI 1.84–5.82, P = 0.000, fixed-effect) and osteosarcomas (pooled HR = 1.95, 95% CI 1.23–3.09, P = 0.005, fixed-effect), apart from reproductive system cancers (pooled HR = 2.16, 95% CI 0.95–4.87, P = 0.065, fixed-effect). When the studies were categorized according to sample sizes, a significant connection was observed between SNHG20 upregulation and inferior OS in large sample sizes (> 100, pooled HR = 2.86, 95% CI 2.09–3.92, P = 0.000, fixed-effect), middle sample sizes (80-100, pooled HR = 2.64, 95% CI 1.81–3.87, P = 0.000, fixed-effect) or small sample sizes (< 80, pooled HR = 2.09, 95% CI 1.56–2.81, P = 0.000, fixed-effect), demonstrating that larger sample sizes might devote to more robust and accurate results. As for different data extraction methods, the subgroup analysis unveiled that...
| Author        | Year | Study region | Recruitment time | Cancer type                  | Age (%) | No. (high/low) | Outcome | Detection method | Cut-off value | Source of HR       | NOS score |
|--------------|------|--------------|------------------|------------------------------|---------|----------------|---------|------------------|---------------|-------------------|-----------|
| Li et al.    | 2016 | China        | 2006–2011        | Colorectal cancer            | ≥ 65    | 107 (54/53)    | OS      | qRT-PCR          | NA            | Data in paper     | 7         |
| Li et al.    | 2017 | China        | 2007–2011        | Hepatocellular carcinoma     | > 65    | 96 (50/46)     | OS      | qRT-PCR          | Median        | Survival curves   | 8         |
| Wang et al.  | 2018 | China        | 2016–2017        | Osteosarcoma                 | ≥ 18    | 32 (18/14)     | OS      | qRT-PCR          | Median        | Survival curves   | 8         |
| Zhang et al. | 2016 | China        | 2006–2009        | Hepatocellular carcinoma     | > 55    | 144 (98/46)    | OS DFS  | ISH              | NA            | Data in paper     | 6         |
| Cui et al.   | 2018 | China        | 2012–2014        | Gastric cancer               | > 55    | 56 (28/28)     | OS DFS  | qRT-PCR          | NA            | Survival curves   | 6         |
| Chen et al.  | 2017 | China        | 2013–2015        | Lung cancer                  | > 65    | 42 (21/21)     | OS PFS  | qRT-PCR          | Median        | Survival curves   | 7         |
| Guo et al.   | 2018 | China        | NA               | Cervical cancer              | ≥ 45    | 93 (47/46)     | OS      | qRT-PCR          | NA            | Survival curves   | 7         |
| Zhang et al. | 2018 | China        | NA               | Esophageal carcinoma         | ≥ 60    | 80 (37/43)     | OS      | qRT-PCR          | Median        | Survival curves   | 6         |
| Gao et al.   | 2018 | China        | 2008–2013        | Oral carcinoma               | > 60    | 40 (20/20)     | OS      | qRT-PCR          | NA            | Data in paper     | 8         |
| Gao et al.   | 2019 | China        | NA               | Glioma                       | ≥ 60    | 78 (33/45)     | OS      | qRT-PCR          | Mean          | Survival curves   | 8         |
| Sun et al.   | 2018 | China        | 2011–2013        | Nasopharyngeal carcinoma     | > 50    | 55 (28/27)     | OS      | qRT-PCR          | Median        | Survival curves   | 6         |
| Wang et al.  | 2019 | China        | NA               | Epithelial ovarian cancer    | > 55    | 60 (38/22)     | OS      | qRT-PCR          | NA            | Survival curves   | 6         |
| Zhang et al. | 2018 | China        | NA               | Osteosarcoma                 | > 18    | 140 (70/70)    | OS      | qRT-PCR          | NA            | Data in paper     | 7         |
| Li et al.    | 2019 | China        | NA               | Laryngeal carcinoma          | ≥ 60    | 56 (28/28)     | OS      | qRT-PCR          | NA            | Survival curves   | 8         |
| Li et al.    | 2019 | China        | 2011–2017        | Glioma                       | ≥ 50    | 108 (54/54)    | OS RFS  | qRT-PCR          | Median        | Data in paper     | 6         |

NO, number; HR, hazard ratio; NOS, Newcastle–Ottawa Scale; NA, not available; OS, overall survival; DFS, disease-free survival; RFS, recurrence-free survival; PFS, progression-free survival; qRT-PCR, quantitative reverse transcription polymerase chain reaction; ISH, in situ hybridization.
the prognostic value of SNHG20 on the OS was not influenced by data extraction methods, that is, the HR provided in the papers (pooled HR = 2.55, 95% CI 1.98–3.29, \( P = 0.000 \), fixed-effect) or extracted from the survival curves (pooled HR = 2.38, 95% CI 1.80–3.14, \( P = 0.000 \), fixed-effect). No severe heterogeneity was checked within the subgroups.

**SNHG20 expression and DFS/RFS/PFS**

Four articles consisting of 350 cases exhibited the prognostic role of SNHG20 on cancer progression or recurrence, with a pooled HR of 2.37 (95% CI 1.60–3.51, \( P = 0.000 \), Fig. 3). Of note, enforced SNHG20 expression predicted a poor performance for DFS/RFS/PFS in the involved cancer types compared with low SNHG20 expression. No any significant heterogeneity existed across studies under a fixed-effect model (\( I^2 = 0.0\% \), \( P = 0.974 \)).

**Correlation between SNHG20 expression and clinical characteristics in patients with cancer**

**TNM stage**

Reports from an aggregate of nine studies declared the correlation of SNHG20 with TNM stage in multiple tumors, with a fixed-effect model on account of limited heterogeneity (\( I^2 = 13.9\% \), \( P = 0.318 \)). The combined analysis highlighted that patients with elevated SNHG20 expression had a tendency for more advanced TNM phase (OR = 2.80, 95% CI 2.00–3.93, \( P = 0.000 \), Fig. 4a, Table 3).

**Tumor size**

In total, six studies with 478 patients were employed to disclose a link between SNHG20 expression and tumor size. Due to insignificant heterogeneity, a fixed-effect framework was adopted (\( I^2 = 0.0\% \), \( P = 0.753 \)). Obviously, this association demonstrated that patients with increased SNHG20 expression, were more liable to develop large tumor size (OR = 3.08, 95% CI 2.11–4.51, \( P = 0.000 \), Fig. 4b, Table 3).

**Lymph node metastasis**

The relationship between SNHG20 expression and lymph node metastasis was evaluated in eight studies containing 534 patients. A fixed-effect model was applied to calculate the accumulated OR and its 95% CI, when there was marginally moderate heterogeneity between studies (\( I^2 = 45.0\% \), \( P = 0.079 \)). The aggregated results suggested
that patients with up-regulated SNHG20 expression preferentially metastasized to the lymph nodes (OR = 2.99, 95% CI 2.08–4.31, P = 0.000, Fig. 4c, Table 3).

**Tumor stage**

Three studies described the tumor stage of 203 patients in the light of different SNHG20 expression levels. No evidence of statistical heterogeneity was found; consequently, a fixed-effect framework was performed to pool the results (I² = 0.0%, P = 0.943). This showed that the patients with augmented SNHG20 expression tended towards high tumor stage (OR = 4.51, 95% CI 2.17–9.37, P = 0.000, Table 3).

**Histological grade**

There were nine studies revealed a connection between SNHG20 expression and histological grade, and data of 844 patients were collected and pooled for reanalysis. A fixed-effect model was utilized for low heterogeneity detected among included studies (I² = 6.0%, P = 0.385). Statistical analyses illustrated the fact that patients with SNHG20 over-expression had a higher risk of poor histological grade (OR = 1.95, 95% CI 1.44–2.63, P = 0.000, Fig. 4d, Table 3).

Nevertheless, no conspicuous association was observed between SNHG20 expression and gender (OR = 0.96, 95% CI 0.74–1.25, P = 0.763, fixed-effect, Table 3), smoking status (OR = 1.16, 95% CI 0.59–2.28,
\( P = 0.676 \), fixed-effect, Table 3) or distant metastasis (\( OR = 1.28, \) 95% CI 0.35–4.71, \( P = 0.706 \), random-effect, Table 3).

**Sensitivity analysis**

A sensitivity analysis was conducted by omitting individual research by turns with the aim to explore the stability of meta-analysis of SNHG20 and OS. As presented in Fig. 5, the cumulative HR was not dramatically impacted, which further substantiated the reliability and validity of our results.

**Assessment of publication bias**

Publication bias was examined with respect to the survival endpoints of OS by introducing Funnel plots, Begg’s and Egger’s test. The symmetrical funnel plot (Fig. 6),

### Table 2 Overall and subgroup meta-analysis of the association between SNHG20 expression and OS

| Subgroup                     | Studies/N | Patient/N | Pooled HR (95% CI) | P value | Heterogeneity | Model |
|------------------------------|-----------|-----------|--------------------|---------|---------------|-------|
| Overall                      | 15        | 1187      | 2.47 (2.05, 2.98)  | 0.000   | 0.00%         | 0.718 Fixed-effect |
| Cancer type                  |           |           |                    |         |               |       |
| Digestive system cancer      | 5         | 483       | 2.91 (2.16, 3.92)  | 0.000   | 0.00%         | 0.726 Fixed-effect |
| Osteosarcoma                 | 2         | 172       | 1.95 (1.23, 3.09)  | 0.005   | 0.00%         | 0.973 Fixed-effect |
| Respiratory system cancer    | 1         | 42        | 3.78 (1.18, 12.09) | 0.025   | –             | –     |
| Reproductive system cancer   | 2         | 153       | 2.16 (0.95, 4.87)  | 0.065   | 0.00%         | 0.390 Fixed-effect |
| Head and neck cancer         | 3         | 151       | 1.97 (1.36, 2.85)  | 0.000   | 0.00%         | 0.722 Fixed-effect |
| Glioma                       | 2         | 186       | 3.27 (1.84, 5.82)  | 0.000   | 50.00%        | 0.157 Fixed-effect |
| Sample size                  |           |           |                    |         |               |       |
| >100                         | 4         | 499       | 2.86 (2.09, 3.92)  | 0.000   | 39.10%        | 0.177 Fixed-effect |
| 80–100                       | 3         | 269       | 2.64 (1.81, 3.87)  | 0.000   | 0.00%         | 0.605 Fixed-effect |
| <80                          | 8         | 419       | 2.09 (1.56, 2.81)  | 0.000   | 0.00%         | 0.929 Fixed-effect |
| Extracted method             |           |           |                    |         |               |       |
| Direct                       | 5         | 539       | 2.55 (1.98, 3.29)  | 0.000   | 36.70%        | 0.176 Fixed-effect |
| Indirect                     | 10        | 648       | 2.38 (1.80, 3.14)  | 0.000   | 0.00%         | 0.903 Fixed-effect |

OS: Overall survival, HR: hazard ratio, 95% CI: 95% confidence interval

**Fig. 3** Meta-analysis for the pooled HRs of DFS/RFS/PFS in patients with various cancers. DFS: disease-free survival, RFS: recurrence-free survival, PFS: progression-free survival, HR: hazard ratio, 95% CI: 95% confidence interval.
**Fig. 4** Forests plots for the association between SNHG20 expression and clinicopathological parameters. **a** TNM stage; **b** tumor size; **c** lymph node metastasis; **d** histological grade. OR odds ratio, 95% CI 95% confidence interval.

**Table 3** Meta analysis results for the association of over-expressed SNHG20 with clinicopathological parameters

| Categories                          | Studies (n) | Number of patients | OR (95% CI)     | P value | Heterogeneity | Begg | Egger |
|-------------------------------------|-------------|--------------------|-----------------|---------|---------------|------|-------|
| Gender (male vs female)             | 13          | 1034               | 0.96 (0.74, 1.25) | 0.763   | 0.00          | 0.607 | 0.951 | 0.792 |
| Smoking status (yes vs no)          | 3           | 137                | 1.16 (0.59, 2.28) | 0.676   | 0.00          | 0.439 | –     | –     |
| Distant metastasis (yes vs no)      | 5           | 502                | 1.28 (0.35, 4.71) | 0.706   | 84.50         | 0.000 | –     | –     |
| TNM stage (III/IV vs I/II)          | 9           | 591                | 2.80 (2.00, 3.93) | 0.000   | 13.90         | 0.318 | 0.348 | 0.389 |
| Tumor size (> 5 cm vs < 5 cm)       | 6           | 478                | 3.08 (2.11, 4.51) | 0.000   | 0.00          | 0.753 | –     | –     |
| Lymph node metastasis (yes vs no)   | 8           | 534                | 2.99 (2.08, 4.31) | 0.000   | 45.00         | 0.079 | –     | –     |
| Tumor stage (T3/T4 vs T1/T2)        | 3           | 203                | 4.51 (2.17, 9.37) | 0.000   | 0.00          | 0.943 | –     | –     |
| Histological grade (poorly vs well/moderately) | 9       | 844                | 1.95 (1.44, 2.63) | 0.000   | 6.00          | 0.385 | 0.602 | 0.575 |

OR odd ratio, 95% CI/95% confidence interval
**Fig. 5** Sensitivity analysis for the correlation between SNHG20 expression with overall survival (OS)

| Study          | Lower CI Limit | Estimate | Upper CI Limit |
|----------------|----------------|----------|----------------|
| Li et al (2016)|                |          |                |
| Liu et al (2017)|              |          |                |
| Wang et al (2018)|             |          |                |
| Zhang1 et al (2016)|           |          |                |
| Cui et al (2018) |              |          |                |
| Chen et al (2017)|            |          |                |
| Guo et al (2018)|             |          |                |
| Zhang et al (2018)|         |          |                |
| Gao et al (2018) |             |          |                |
| Gao et al (2019) |             |          |                |
| Sun et al (2018) |             |          |                |
| Wang et al (2019)|           |          |                |
| Zhang2 et al (2018)|         |          |                |
| Li1 et al (2019) |              |          |                |
| Li2 et al (2019) |              |          |                |

**Fig. 6** Funnel plot of the publication bias for overall survival (OS)
together with the outcomes of Begg’s (P = 0.553) and Egger’s test (P = 0.899), disclosed no distinct publication bias for OS. Furthermore, there was no evidence in favor of publication bias in terms of TNM stage, histological grade, and gender (Table 3). However, analysis of publication bias was inappropriate for tumor size, lymph node metastasis, tumor stage, smoking status, and distant metastasis, owing to the insufficient number of qualified publications in the meta-analysis.

Discussion
LncRNAs originally considered as transcriptional noise, have today been demonstrated to be implicated in manifold human malignancies [5]. Moreover, dysregulation of LncRNAs has been correlated with cancer cellular development by interfering with alternative splicing of pre-mRNA, by acting as a regulator in the transcription factor and histone-modifying enzyme, or by affecting the steps of translation and protein folding [26, 27]. Hence, the ectopic expression of LncRNAs could have a potential power for monitoring tumors and serving as a promising predictor of survival [28].

Previous published studies have elucidated that SNHG20 was a cancer-related LncRNA and had an indispensable role in oncogenic activity. For instance, SNHG20 has been demonstrated to promote tumor growth through functioning as a competing endogenous RNA (ceRNA) of miR-154 in non-small cell lung cancer and modulating the expression of ZEB2 and RUNX2 [29]. Additionally, SNHG20 could exert its carcinogenic action in breast cancer, and high level of SNHG20 could facilitate the proliferation, invasion and metastasis of cancer cells via modulating miR-495/HER2 axis [30]. Meanwhile, SNHG20 also elevated tumor progression by controlling the epithelial-to-mesenchymal transition (EMT) signaling pathway in osteosarcoma or hepatocellular carcinoma [23, 24, 31], activating PI3K/Akt/mTOR pathway in glioblastoma [25], as well as upregulating the expression of transforming growth factor-β1 (TGF-β1) in nasopharyngeal carcinoma [18], etc. Given these above molecular mechanisms of SNHG20 among various carcinomas, it was obvious that SNHG20 was connected with an unfavorable prognosis in cancer patients, which further provided support for clinical utility of SNHG20.

We aimed at exploring the relationship between SNHG20 expression levels and prognosis of human carcinomas in the present comprehensive meta-analysis, which pooled a total of 15 independent studies with 1187 tumor sufferers. The results of the research uncovered that enhanced SNHG20 expression was predominantly interrelated with short OS in cancer patients. Subgroup analyses were exploited to maximize clinical relevance. In the subgroup analysis according to cancer types, augmented SNHG20 expression was significantly related to poor OS in respiratory system cancers, gliomas, digestive system cancers, head and neck neoplasms as well as osteosarcomas, but not in cancers of the reproductive system. The reasons for the above phenomenon may be the difference in the age distribution of patients or the origin of tumor cells. Besides, we discovered that neither sample sizes nor data extraction methods altered the overall results. Subsequently, the outcomes from the sensitivity analysis and publication bias assessment also further verified the representativeness and reliability of our analysis. In addition, we identified that there was a strong link between SNHG20 overexpression and unfavorable DFS/RFS/PFS, meaning that cohorts with elevated SNHG20 expression exhibited a higher risk of tumor relapse or progression. Likewise, the clinicopathologic analyses manifested that patients with the high SNHG20 expression levels had increased occurrence probability of advanced TNM stage, large tumor size, positive lymph node metastasis, high tumor stage, and poorly differentiated grade. However, no prominent correlation was found between SNHG20 expression and gender, smoking status or distant metastasis. Taken together, the anomalous modulation of SNHG20 across different kinds of cancers suggests that SNHG20 is qualified as a candidate biomarker for both forecasting poor prognosis and providing therapeutic targets in cancer patients.

Nonetheless, we acknowledge several limitations in this work that should be pointed out. First of all, each and every enrolled study was performed in China, which increases the risk of geographical bias. Second, the sample sizes of some research and the included cancer types were comparatively smaller, which may bring about small-study effects. Third, the Cut-off level of high and low SNHG20 expression level was distinct across studies and not all of them provided this parameter, which perhaps reduces the reliability of our results. Fourth, HR with 95% CI was indirectly reckoned by survival curves in some papers, which are less precise than those directly extracted from the original articles. Last, despite our primary outcomes were lack of heterogeneity, the predictive significance of SNHG20 in multiple human tumors might be exaggerated to some extent. Consequently, high-quality studies that are at large-scale are necessary for the verification of our conclusion.

Conclusions
In aggregate, the present meta-analysis elucidated that elevated SNHG20 expression is frequent in plenty of various types of cancers and qualified as a dependable and novel predictive factor of poor prognosis and clinicopathological features in cancer patients. Nevertheless, higher-quality multicenter studies with a larger sample...
capacity are still needed to corroborate and enhance the clinical application of SNHG20 in human malignancies.

Abbreviations
SNHG20: Small nuclear RNA host gene 20; LncRNAs: Long non-coding RNAs; ceRNA: Competing endogenous RNA; OS: Overall survival; DFS: Disease-free survival; RFS: Recurrence-free survival; qRT-PCR: Quantitative reverse transcription polymerase chain reaction, HCC: Hepatocellular carcinoma; ISH: In situ hybridization; TNM: Tumour-node-metastasis; TGF-β1: Transforming growth factor-β1; NOS: Newcastle–Ottawa Scale; EMT: Epithelial-to-mesenchymal transition; HR: Hazard ratio; OR: Odds ratio; CI: Confidence interval.

Acknowledgements
Not applicable.

Authors’ contributions
HLZ, SZ, RNJ contributed to conception and design of the study. HLZ and QPL collected and analyzed the data. FW and XXG made some tables and figures. HLZ and SZ wrote the manuscript. HSW, RYT and XCW participated in the revision of the manuscript. All authors reviewed the final manuscript. All authors read and approved the final manuscript.

Funding
This research work was supported by the Project of Standard Diagnosis and Treatment of Key Disease of Jiangsu Province (BE2015722).

Availability of data and materials
The datasets during the current study are available from the corresponding author on reasonable request.

The datasets during the current study are available from the corresponding author on reasonable request.

Funding
This research work was supported by the Project of Standard Diagnosis and Treatment of Key Disease of Jiangsu Province (BE2015722).

Acknowledgements
Not applicable.

Authors’ contributions
HLZ, SZ, RNJ contributed to conception and design of the study. HLZ and QPL collected and analyzed the data. FW and XXG made some tables and figures. HLZ and SZ wrote the manuscript. HSW, RYT and XCW participated in the revision of the manuscript. All authors reviewed the final manuscript. All authors read and approved the final manuscript.

Funding
This research work was supported by the Project of Standard Diagnosis and Treatment of Key Disease of Jiangsu Province (BE2015722).

Availability of data and materials
The datasets during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Not applicable.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 23 November 2019 Accepted: 6 July 2020
Published online: 11 July 2020

References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
3. Huynh HP, Anderson BA, Gulilat F, McAllindon A. Emerging roles for long noncoding RNAs in skeletal biology and disease. Connect Tissue Res. 2017;58(1):116–41.
4. Gugnoni M, Ciarrocchi A. Long noncoding RNA and epithelial mesenchymal transition in cancer. Int J Mol Sci. 2019;20(8):1924.
5. Miranda-Castro R, de-Los-Santos-Alvarez N, Lobo-Castanon MJ. Long noncoding RNAs: from genomic junk to rising stars in the early detection of cancer. Anal Bioanal Chem. 2019;411(19):4265–75.
6. Sanchez Calle A, Kawamura Y, Yamamoto Y, Takeshita F, Ochiya T. Emerging roles of long non-coding RNA in cancer. Cancer Sci. 2018;109(7):2093–100.
7. Zhao W, Ma X, Liu L, Chen Q, Liu Z, Zhang Z, Ma S, Wang Z, Li H, Wang Z, et al. SNHG20: a vital IncRNA in multiple human cancers. J Cell Physiol. 2019;11:3238–45.
8. Zhang D, Cao C, Liu L, Wu D. Up-regulation of LncRNA SNHG20 predicts poor prognosis in hepatocellular carcinoma. J Cancer. 2016;7(5):608–17.
9. Zhao Q, Gao S, Du Q, Liu Y. Long non-coding RNA SNHG20 promotes bladder cancer via activating the Wnt/beta-catenin signalling pathway. Int J Mol Med. 2018;42(5):2839–48.
10. Wang W, Luo P, Guo W, Shi Y, Xu D, Zheng H, Jia L. LncRNA SNHG20 knockdown suppresses the osteosarcoma tumorigenesis through the mitochondrial apoptosis pathway by miR-139/RUNX2 axis. Biochem Biophys Res Commun. 2018;503(3):1927–33.
11. Li XS, Shen FZ, Huang LX, Hui L, Liu RH, Ma YJ, Jin BZ. LncRNA small nuclear RNA host gene 20 predicts poor prognosis in glioma and promotes cell proliferation by silencing P21. Onco Targets Ther. 2019;12:805–14.
12. Li C, Zhou L, He J, Fang XQ, Zhu SW, Xiong MM. Increased long non-coding RNA SNHG20 predicts poor prognosis in colorectal cancer. BMC Cancer. 2016;16:655.
13. Cui N, Liu J, Xia H, Xu D. LncRNA SNHG20 contributes to cell proliferation and invasion by upregulating ZFX expression in the miR-495-3p axis in gastric cancer. J Cell Biochem. 2019;120(3):3114–23.
14. Chen Z, Chen X, Chen M, Tie M, Sun S, Nie F, Lu B, Zhang T, Zhou Y, Chen Q, Wei C, et al. Long non-coding RNA SNHG20 promotes non-small cell lung cancer cell proliferation and migration by epigenetically silencing of P21 expression. Cell Death Dis. 2017;8(10):e3092.
15. Guo H, Yang S, Li S, Yan M, Li L, Zhang H. LncRNA SNHG20 promotes cell proliferation and invasion via miR-140-3p-ADAM10 axis in cervical cancer. Biomed Pharmacother. 2018;102:749–57.
16. Zhang C, Jiang F, Su C, Xie P, Xu L. Upregulation of long non-coding RNA SNHG20 promotes cell growth and metastasis in esophageal squamous cell carcinoma via modulating ATM-JAK-PD-1 pathway. J Cell Biochem. 2019;120(1):1164–21.
17. Gao P, Fan R, Ge T. SNHG20 serves as a predictor for prognosis and promotes cell growth in oral squamous cell carcinoma. Oncol Lett. 2017;11(7):1951–7.
18. Sun C, Sun Y, Zhang E. Long non-coding RNA SNHG20 promotes nasopharyngeal carcinoma cell migration and invasion by upregulating TGF-beta1. Exp Ther Med. 2018;16(6):4967–74.
19. Wang D, Dai J, Hou S, Qian Y. LncRNA SNHG20 predicts a poor prognosis and promotes cell progression in epithelial ovarian cancer. Biosci Rep. 2019. https://doi.org/10.1042/BSR20182186.
20. Li Y, Xu J, Guo YN, Yang BB. LncRNA SNHG20 promotes the development of laryngeal squamous cell carcinoma by regulating miR-140. Eur Rev Med Pharmacol Sci. 2019;23(8):3401–9.
21. Tiemey JJ, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
22. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–34.
23. Liu J, Lu C, Xiao M, Jiang F, Qu L, Ni R. Long non-coding RNA SNHG20 predicts a poor prognosis for HCC and promotes cell invasion by regulating the epithelial-to-mesenchymal transition. Biomed Pharmacother. 2017;89:857–63.
24. Zhang J, Ju C, Zhang W, Xie L. LncRNA SNHG20 is associated with clinical progression and enhances cell migration and invasion in osteosarcoma. JUBMB Life. 2018;70(11):1115–21.
25. Gao XF, He HQ, Zhu XB, Xie SL, Cao Y. LncRNA SNHG20 promotes tumorigenesis and cancer stemness in glioblastoma via activating PI3K/Akt/mTOR signaling pathway. Neoplasia. 2019;21(6):532–42.
26. Sarfi M, Abbastabar M, Khalili E. Long non-coding RNA host gene 20 predicts poor prognosis in glioma and promotes cell invasion by regulating the epithelial-to-mesenchymal transition. Biomed Pharmacother. 2017;89:857–63.
27. Zhang J, Ju C, Zhang W, Xie L. LncRNA SNHG20 is associated with clinical progression and enhances cell migration and invasion in osteosarcoma. JUBMB Life. 2018;70(11):1115–21.
28. Balas MM, Johnson AM. Exploring the mechanisms behind long noncoding RNAs and cancer. Noncoding RNA Res. 2018;3(1):108–17.
29. Lingling J, Xiangao J, Guiqing H, Jichan S, Feifei S, Haiyan Z. SNHG20 knockdown suppresses proliferation, migration and invasion, and promotes apoptosis in non-small cell lung cancer through acting as a miR-154 sponge. Biomed Pharmacother. 2019;112:108648.
30. Guan YX, Zhang MZ, Chen XZ, Zhang Q, Liu SZ, Zhang YL. Lnc RNA SNHG20 participated in proliferation, invasion, and migration of breast cancer cells via miR-495. J Cell Biochem. 2018;119(10):7971–81.
31. Pang A, Carbini M, Moreira AL, Maki RG. Carcinosarcomas and related cancers: tumors caught in the act of epithelial–mesenchymal transition. J Clin Oncol. 2018;36(2):210–6.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.